ECMO Machine Market to Reach USD 0.7 Billion by 2035, Asia Pacific Leads with 51% Share

According to the report, the global ECMO Machine Market is anticipated to grow from USD 0.4 Billion in 2025 to USD 0.7 Billion in 2035 at a CAGR of 4.3% during the forecast. The ECMO machine market is growing rapidly, driven by enhanced awareness and use of the devices globally, especially during the pandemic and preceding COVID-19 effects, and demonstrated applications in cardiac and respiratory failure. Growth in the number of ECMO centers and with the stated increase in ECMO transport teams, the use addresses increased interest in both higher-resourced and growing-based healthcare systems.

Notably, systems are being miniaturized and made more autonomous to limit the number of actions while increasing safety in critical care environments. Hybrid ECMO systems with an integrated artificial intelligence monitoring aspect are in testing at a few tertiary care centers in the US and Swedon to initiate and provide predictive alerts on clot formation, interruptions in flow, and performance of oxygenator performance. A number of startups are also exploring wearable ECMO prototypes with potential bridge-to-transplant applications.
Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the ECMO Machine Market Research Report: https://marketgenics.co/press-releases/extracorporeal-membrane-oxygenation-ecmo-machine-market-61050

Regional Analysis of ECMO Machine Market

The Asia-Pacific ECMO machine market is the largest to date given the increase in critical care infrastructure investment; increased awareness of advanced life support technology; increased demand for respiratory support systems and cardiac support devices. Countries in the region such as Japan, South Korea and China have advanced ICU networks and increasing interest and adoption of portable ECMO systems. The response to Covid-19 has expedited ECMO training and established capacity for cities, especially urban hospitals.

Furthermore, North America has developed its ECMO markets; there is strong demand in the USA with significant ECMO centers and greater ECMO awareness and interest in innovation, such as the use of AI for monitoring systems. Europe also has consistent growth potential as we see in countries such as Germany and France, even the UK, due to significant government investment in public health and government related research from academic and training institutes.

Additionally, Latin America as well as Middle East and African markets are slower right now but growth is steadily aligning with advancements in critical care access and response preparedness policies likely coming from developed government investment into social, economic and emergency service policies.

Key players in the global ECMO Machine Market include prominent companies such as Abbott Laboratories, Abiomed Inc., ALung Technologies, Inc., Andocor N.V., Cardiohelp (Getinge), Eurosets S.r.l., Fresenius Medical Care AG & Co. KGaA, Getinge AB, Hemovent GmbH, LivaNova PLC, MC3 Cardiopulmonary, Medos Medizintechnik AG, Medtronic plc, Microport Scientific Corporation, Nipro Corporation, OriGen Biomedical, Inc., Senko Medical Instrument Mfg. Co., Ltd., Spectrum Medical, Terumo Corporation, Xenios AG (a Fresenius Medical Care Company), and other key players, along with several other key players contributing to market growth through innovation, strategic partnerships, and global expansion.

To know more about the ECMO Machine Market - Download our Sample Report:https://marketgenics.co/download-report-sample/extracorporeal-membrane-oxygenation-ecmo-machine-market-61050

Key Driver, Restraint, and Growth Opportunity Defining the Global ECMO Machine Market

The primary driver of the ECMO machine market is the greater awareness of ECMO as a life-saving treatment for severely compromised patients with cardiac or respiratory dysfunction. The importance of clinical value was recognized globally during COVID-19, with many hospitals/hospital systems investing in critical care during this pandemic. As technology advances, features such as automated controls, enhanced sensor integration, and user-friendly interfaces and display panels will reduce operational complexity, allowing continuous adoption of ECMO across ICUs (intensive care units) around the world, particularly in developed countries.

However, economic and operator resource restrictions limit the feasibility for hospitals to adopt ECMO and contribute to limiting development. Operating ECMO machines is costly, particularly due to equipment and ongoing operational costs (including highly trained perfusionist resources and 24-hr access to qualified episodic clinical resources). The extremely high and intensive resource and budget requirements limit the penetration of ECMO technology to tertiary hospitals with significant resource requirements or in high-resourced academic hospitals.

Furthermore, a unique opportunity for long-range growth in the ECMO machine market comes from developing small, portable, or transportable ECMO systems. Development and miniaturization of ECMO machines could allow for the use of portable ECMO systems outside acute-care hospitals in the pre-hospital or rural critical care setting. Companies are interested in investing in portable systems that can support a miniaturized, lightweight, rapid-deployment ECMO systems.

Buy Now: https://marketgenics.co/buy/extracorporeal-membrane-oxygenation-ecmo-machine-market-61050

Recent Development and Strategic Overview:

In July 2025, Getinge AB unveiled the new Cardiohelp XL ECMO System, raising the bar for mobility and digital support in critical care. The Cardiohelp XL comes equipped with AI-driven monitoring, an even lighter and more portable design, and an intuitive, larger touchscreen interface that guides workflows for setup and troubleshooting. With its built-in electronic gas blender, upgraded reliability, and integration of near-infrared spectroscopy (NIRS) for real-time oxygenation monitoring, clinicians can confidently manage ECMO support across the hospital or during transport-making fast, informed decisions.

In June 2025, Medtronic launched the VitalFlow ECMO System, following its CE Mark approval in Europe. The VitalFlow platform is all about making ECMO therapy as streamlined and approachable as possible, featuring a configurable one-system solution with a fully integrated, intuitive interface that allows every ICU team member-no matter their experience level-to operate and manage ECMO confidently. VitalFlow's modular architecture supports both bedside care and hospital transport, while its design-born through the Medtronic acquisition of MC3 Cardiopulmonary.

Get a preview of our ECMO Machine Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/extracorporeal-membrane-oxygenation-ecmo-machine-market-61050

Key Trend: Technological Streamlining, Mobility Enhancements, and Expanded Indications Drive Market Evolution

Next-generation extracorporeal membrane oxygenation (ECMO) systems are becoming smaller, more portable, and more intuitive adding to their potential use in mobile units and inter-hospital transfer. With the new automation features and built-in monitoring, systems are reducing his dependence on specialized personnel.

Moreover, the expanded use of ECMO in protocols for severe ARDS, cardiac arrest, and perioperative support is extending its indications as a clinical therapy. More awareness and better documentation of ECMO training programs anticipated to help further reduce the global shortage of qualified operators.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.